GET DAILY SIGNALSCarlsmed (CARL) Analyst Targets Point to +18% Upside Potential
Key Takeaways
- The $19 central target is the arithmetic mean of five verified analyst price targets, which range from roughly $16 to $24.
- At a recent price near $16.05, reaching $19 implies an upside of roughly 18% — a substantial move that would require clearing the stock's 52-week high.
- All five tracked analysts rate the stock a Buy, but their views differ materially on how fast the business can scale toward profitability.
- The main supports are rapid revenue growth and the company's AI-enabled spine surgery platform, while the main risks are ongoing losses and early-stage execution.
- For additional context, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- For broader market coverage, explore Trending AI Robots.
Analyst Targets and Consensus View
Carlsmed, Inc. (CARL), based in Carlsbad, California, develops the aprevo platform that combines AI-enabled planning software with custom 3D-printed implants for spine fusion procedures. A small group of Wall Street analysts covers the stock, and every one of them currently assigns a Buy rating.
I looked at five individually attributable targets: BTIG at $24 (October 2026), Truist Securities at $20 (August 2026), Piper Sandler at $18 (August 2026), Needham at $17 (July 2026), and Goldman Sachs at $16 (May 2026). Their average comes to $19.00. The spread from $16 to $24 shows real differences of opinion on valuation and the speed of commercial adoption rather than a narrow consensus.
The more optimistic targets rest on the aprevo platform’s personalized approach to spine surgery and the steep revenue ramp the company has posted. More conservative estimates reflect the fact that CARL is still unprofitable and in the early stages of scaling its commercial operations.
Current Market Position and Path to the Target
The most recent verified price sits near $16.05, close to the upper end of the 52-week range of $8.50 to $17.23. Getting to $19 would mean an upside of roughly 18%, which first requires a clear break above the $17.23 high and then a move through the $18 area.
Fundamentals underpin that path more than momentum alone. Trailing-twelve-month revenue of about $63 million grew roughly 65% year over year, while full-year 2025 revenue reached about $50.5 million, up roughly 86% from the prior year. The company still reports net losses, so valuation rests on a price-to-sales multiple rather than earnings, which keeps the outlook tied to continued top-line execution.
Factors That Could Support a Move Higher
Several elements could help the stock advance. The aprevo platform targets a sizable spine-surgery market with a differentiated, personalized implant solution, and the company expanded its offerings with the U.S. launch of the aprevo Lumbar Bi-lateral Posterior System in October 2026. Revenue growth remains strong, and the balance sheet looks solid with roughly $89 million in cash against modest debt.
Analyst revisions have been constructive as well. BTIG lifted its target to $24 from $23, and Truist raised its target to $20 from $18, showing greater confidence in the commercial outlook. A healthy cash position and growing institutional interest add further support. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Risks That Could Keep the Target Out of Reach
The biggest concern remains profitability. Carlsmed continues to post negative net income and negative operating margins, so the investment case hinges on future growth rather than current earnings. As a commercial-stage company with a modest revenue base and relatively thin float, the stock can be volatile and sensitive to any quarterly shortfall.
Competition adds another layer: the spine-implant market is dominated by large, well-capitalized device makers with established sales channels and surgeon relationships. Slower-than-expected adoption, reimbursement or regulatory hurdles, or a broader shift away from unprofitable growth names could all pressure valuation and delay any move toward $19.
Technical Levels to Watch
The 52-week high of $17.23 remains the key near-term resistance level. A sustained break above it would mark the first meaningful step toward the $19 target. On the downside, the 50-day moving average near $14.9 and the 200-day moving average near $12.5 sit well below the current price and confirm the intermediate uptrend. The $14.5–$15 consolidation zone offers potential support if momentum pauses.
Time Horizon and Key Items to Monitor
Analyst price targets generally reflect a roughly 12-month horizon, though assumptions vary across firms. Investors should focus on quarterly earnings and guidance—the company reported third-quarter 2026 results in November—along with revenue growth, gross-margin trends, and commentary on aprevo adoption and reimbursement. Analyst revisions, new product launches, and any FDA or regulatory updates are also important variables that could shift the target range.
Using AI Daily Buy/Sell Signals
For traders who want to track shorter-term moves alongside the longer-term analyst targets, Tickeron’s AI Daily Buy/Sell Signals provide a useful data-driven layer. The system applies artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on evolving market conditions and technical behavior. I have found this helps surface opportunities and monitor positions more efficiently than manual review alone, and it fits naturally into a broader research workflow.
Final Assessment
The $19 central target, the average of five analyst targets spanning $16 to $24, sits roughly 18% above the recent price near $16.05. The case for reaching it rests on rapid revenue growth, a differentiated AI-enabled spine platform, a strong cash position, and favorable analyst revisions. The counterarguments center on ongoing losses, intense competition, and the need to first clear the 52-week high. While all analysts are bullish, the wide spread in targets highlights genuine uncertainty about the pace of commercialization. Whether $19 proves achievable will depend mainly on continued revenue acceleration and clearer signs of progress toward profitability in upcoming quarterly reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CARL in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 27, 2026
CARL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 11 similar instances where the stock broke above the upper band. In 10 of the 11 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 17 cases where CARL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for CARL entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CARL as a result. In 21 of 26 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for CARL just turned positive on October 22, 2026. Looking at past instances where CARL's MACD turned positive, the stock continued to rise in 8 of 11 cases over the following month. The odds of a continued upward trend are 73%.
CARL moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CARL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 4 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 44%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARL advanced for three days, in 59 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.706) is normal, around the industry mean (4.477). P/E Ratio (-6.214) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.596) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. CARL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement